Interview with Pharma Board – Glenn Saldanha, Managing Director & CMD, Glenmark

Interview Glenn Saldanha, Managing Director & CEO, Glenmark Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it across 140 countries. What stage of the process are you in? When will we see India’s first novel drug in pharmacies and hospitals? I cannot say too much about Crofelemer, because of confidentiality issues and various other externalities. But very clearly, we are quite excited by the opportunity to launch the drug in the 140 countries where we have acquired the rights. Read More

ˆ Back To Top